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Abstract
Background: The multifunctional β-galactoside-binding protein galectin-3 is found in many distinct subcellular
compartments including the cell nucleus. Expression and distribution of galectin-3 between the cell nucleus and
the cytosol changes during cell differentiation and cancer development. Nuclear functions of galectin-3 and how
they contribute to tumorigenesis are not understood.
Methods: In order to identify nuclear galectin-3 interaction partners, we used affinity chromatography and
co-immunoprecipitation. Spatial proximity in the nucleus was assessed by immunofluorescence and proximity
ligation assay. We also investigated the function of galectin-3 on mRNA-export by fluorescence in situ hybridization
and on mRNA-processing by RNA-sequencing.
Results: The heterogeneous ribonucleoprotein particle component hnRNPA2B1 was identified as a novel galectin-3
binding protein that associates with the lectin in a lactose-dependent manner in the cell nucleus. Specific individual
depletion of galectin-3 does not affect the mRNA distribution between cytoplasm and nucleus. A significant alteration
of this distribution was observed after combined depletion of galectin-1 and −3. However, silencing of galectin-3 was
sufficient to alter the splicing patterns of several genes.
Conclusions: Galectin-3 and hnRNPA2B1 interact as members of the early splicing machinery. Galectin-3 and −1 have
redundant functions in mRNA transport and at least in part in mRNA splicing. RNA-sequencing data points to a specific
function of the hnRNPA2B1/galectin-3 interaction in the processing of transcripts coding for the nuclear oncoprotein SET.
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Background
The galectins are a family of small soluble sugar binding
proteins characterized by a carbohydrate recognition
domain (CRD). This CRD shows a conserved sequence
motif and has a high affinity for β-galactosides [1]. The
family comprises 15 mammalian galectins with one or two
CRDs. Part of the lectin family is distributed in many differ-
ent cell types (galectin-1, galectin-3, galectin-8, galectin-9),
while galectin-2, galectin-4 and galectin-7 show a more
restricted distribution. According to their domain composi-
tion, galectins have been classified into three subgroups,
the prototype, the tandem repeat and the chimeric type.
Prototype and chimeric type galectins contain one single
CRD, whereas tandem repeat galectins are composed of
two CRDs. Galectin-3 is the sole chimeric type galectin. It
is composed of a proline- and glycin-rich amino-terminal
domain fused to a carboxy-terminal CRD. Galectin-3 can
be detected intracellularly in transport vesicles, the cyto-
plasm and the nucleus as well as in the extracellular milieu
[2, 3]. The subcellular distribution of galectin-3 depends on
the cell type and the proliferation stage [4–6]. This protein
is involved in a large number of physiological and patho-
logical processes such as cell proliferation, differentiation,
survival, apoptosis, intracellular trafficking and tumor pro-
gression [7, 8]. Galectin-3 expression changes with tumor
category. In cancers of the thyroid, liver, stomach, and cen-
tral nervous system the protein is upregulated, whereas in
cancers of the breast, ovary, uterus and prostate galectin-3
is downregulated (reviewed in [9]). Moreover, the subcellu-
lar distribution of galectin-3 varies among different tumor
types. In tongue carcinoma cells galectin-3 is translocated
from the nucleus to the cytoplasm during neoplastic pro-
gression [10]. In human colon and prostate carcinoma cells
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galectin-3 is generally down-regulated and consistently ex-
cluded from the nucleus [11]. On the other hand, in
esophageal squamous cell carcinoma patients elevated ex-
pression of galectin-3 in the nucleus is a significant patho-
logical parameter related to histological differentiation and
vascular invasion [12].
Nuclear galectin-3 has a wide range of functions, one
of them is the regulation of gene transcription. Galectin-
3 promotes trans-activation functions of transcription
factors CREB and Sp1, and induces cyclin D1 promoter
activity in human breast epithelial cells [13]. Galectin-3
also modulates gene transcription by the interaction with
the nuclear thyroid-specific transcription factor TTF-1
[14]. As transcriptional co-regulator, galectin-3 also binds
Suppressor of fused, a negative regulator of the hedgehog
signal-transduction pathway shuttling between the cyto-
plasm and the nucleus [15]. Another role of nuclear
galectin-3 is its function as a pre-mRNA splicing factor.
Early experiments already revealed that galectin-3 inter-
acts with components of the nuclear ribonucleoprotein
complex (hnRNP) [16]. Thereafter, a requirement for
galectin-3 in pre-mRNA splicing was reported [17].
In our previous studies we observed an increase in nu-
clear translocation of galectin-3 in clear cell renal cell
carcinoma cells [18]. To gain a better understanding of
the nuclear functions of galectin-3 we now searched for
putative galectin-3 binding partners in nuclear extracts
and identified the heterogeneous ribonucleoprotein par-
ticle component hnRNPA2B1. Galectin-3 as well as
hnRNPA2B1 co-localize in splicing factor enriched sub-
nuclear speckles. Specific depletion of the two galectins,
galectin-1 and −3, affects mRNA-export from the nu-
cleus as assessed by fluorescence in situ hybridization.
Single knockdown of galectin-3 alters the splicing patterns
of several genes, including the SET-oncogene, which is
also affected in hnRNPA2B1-depleted cells.
Methods
Antibodies, plasmid, siRNAs and oligos
Monoclonal (mAb) anti-galectin-3 (M3/38), mAb anti-
galectin-3 (A3A12), mAb anti-galectin-1 (C-8) and poly-
clonal (pAb) anti-galectin-3 (H-160) antibodies were
purchased from Santa Cruz Biotech, Dallas, U.S. MAb
anti-Sc35, mAb anti-hnRNPA2B1 (DP3B3) and pAb
anti-hnRNPA2B1 antibodies were obtained from Abcam,
Cambridge, U.K. MAb anti-U2AF65 (MC3) and mAb
anti-α-tubulin (DM1A) antibodies were purchased from
Sigma-Aldrich, St. Louis, U.S. Secondary Alexa-coupled
antibodies used for immunofluorescence were obtained
from Invitrogen, Darmstadt, Germany.
Specific siRNAs 5’-CACGGTGAAGCCCAATGCAAA-3’
(NM_001177388) for galectin-3-depletion were purchased
from Qiagen and siRNA sc-35441 for galectin-1-depletion
was obtained from Santa Cruz Biotech, Dallas, U.S. For
control experiments firefly luciferase-siRNA was used.
Biotin-oligo(dT) for the FISH-assay was obtained from
Eurofins MWG Operon, Ebersberg, Germany, and the
secondary streptavidin-Alexa Fluor 546 antibody was pur-
chased from Invitrogen, Darmstadt, Germany.
Cell culture and transfection
Human cervix carcinoma cells (HeLa) were cultured
in DMEM high glucose/10 % FCS, 2 mM glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin. Human
kidney clear cell carcinoma cells (RCC-FG1) were cultured
in Mc Coy’s 5a/10 % FCS, 2 mM glutamin at 37 °C and
high humidity. HeLa cells were transfected by electropor-
ation with the Biorad Gene Pulser II. Up to 15 μg of siRNA
were used for silencing of galectin-3 and/or galectin-1. For
successful depletion the cells were transfected twice and
harvested 48 h thereafter.
Immunofluorescence, FISH and fluorescence microscopy
Fluorescence microscopy was performed with fixed HeLa
cells essentially as described before [19]. Fluorescence in
situ hybridization (FISH) was performed with fixed HeLa
cells according to Chakraborty and Fontoura [20]. Cells
were fixed with 4 % paraformaldehyde and perme-
abilized with 0.5 % Triton X-100 for 5 min at 4 °C. Pre-
hybridization-mix (2 x SCC (3 M NaCl, 300 mM triso-
dium citrate, pH 7), 1 mg/mL tRNA, 10 % dextran-sulfate,
25 % formamide) was added to the cells and incubated
for 15 min at 42 °C. The samples were then shifted to
hybridization-mix (2 x SCC, 1 mg/mL tRNA, 10 %
dextran-sulfate, 25 % formamide, 50 μg/mL Biotin-
oligo(dT)) and incubated overnight at 42 °C followed
by Streptavidin Alexa Fluor 546 incubation in PBS/
0.2 % Triton X-100 for 30 min at room temperature.
Confocal images were recorded on a Leica TCS SP2
microscope with a 40x objective (HCX PL APO CS 40x/
1.25–0.75 oil), analyzed with LAS AF (Leica) and quanti-
fied with ImageJ.
Proximity ligation assay
The in situ Proximity Ligation Assay (PLA) was per-
formed by using the Duolink in situ kit purchased from
Olink Bioscience. Cells were fixed with 4 % paraformal-
dehyde and permeabilized with 0.1 % Triton X-100 for
4 min at room temperature. The cells were blocked by
adding blocking solution (Duolink) for 1 h at 37 °C.
Monoclonal anti-galectin-3 A3A12 and polyclonal anti-
hnRNPA2B1 were incubated overnight at 4 °C. Duolink
in situ PLA probes anti-mouse PLUS and anti-rabbit
MINUS were added and incubated for 1 h at 37 °C.
Ligation-reaction and ligase were added followed by in-
cubation for 30 min at 37 °C. Amplification was carried
out for 100 min at 37 °C followed by fluorescence mi-
croscopy of the samples.
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Co-immunoprecipitation and BN-PAGE
Nuclear extracts (NE) from RCC FG1 cells and HeLa
cells were prepared with NE-PER nuclear and cytoplasmic
extraction reagents-kit obtained from Thermo Scientific,
Dreieich, Germany. The buffer was changed to RIPA
buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1 % Triton X-100, 1 % sodium deoxycholate,
0.1 % SDS) by using Amicon Ultra-0.5 centrifugal filter
units with ultracell-10 membrane (Merck Millipore,
Schwalbach, Germany). For co-immunoprecipitation
the Dynabeads M-280 sheep anti-rabbit IgG and the
immunoprecipitation kit purchased from life technologies
was used. NE were incubated with antibody-coupled
Dynabeads for 20 min at room temperature. Samples
were analyzed by SDS-Page and Western Blot. Blue native
polyacrylamide gel electrophoresis (BN-PAGE) was per-
formed essentially as described by Fiala and Blumenthal
[21]. NE from HeLa cells were incubated in native sample
buffer (50 mM BisTris, 125 mM 6-AcA, 0.1 % Triton X-
100, pH 7.0). After 10 min 0.5 % coomassie brilliant blue
G250 was added and incubated for 5 min at 4 °C. The
samples were separated on 20 to 8 % native gradient gels.
Second dimension was separated by 10 % SDS-PAGE and
then transferred on a PVDF membrane for immunoblot.
Protein purification, affinity chromatography and mass
spectrometry
Recombinant human galectin-3 was isolated essentially
as described before [22]. For the generation of affinity
chromatography columns recombinant human galectin-
3 was coupled on a HiTrap NHS-activated HP column
(GE Healthcare) via primary amines. The column was
washed with HCl (1 mM) and galectin-3 was circulated
on the column for 60 min at 4 °C. Non-specifically bound
ligands were removed with buffers A (0.5 M ethanol-
amine, 0.5 M NaCl, pH 8.3) and B (0.1 M sodium acetate,
0.5 M NaCl, pH 4). The column was equilibrated at room
temperature followed by washing with buffers A, B and
excess PBS. Putative interaction partners were eluted with
elution buffer (150 mM lactose in PBS) and protein-rich
fractions (absorption at 280 nm) were processed for mass
spectrometry in MALDI-TOF or in MALDI-TOF-TOF
mode, using a Voyager DE STR instrument (PerSeptive
Biosystems, Framingham, USA) or an Ultraflex Instrument
(Brucker, Germany).
RNA-seq sample preparation and RNA-seq analysis
HeLa cells were transfected with siRNA to silence galectin-
3 and with the non-silencing control siRNA against firefly
luciferase. Total RNA was isolated with the RNeasy Mini
Kit (Qiagen) and processed by the TruSeq® Stranded
mRNA LT Kit to prepare RNA-seq libraries. The libraries
were sequenced on an Illumina HiSeq 1500 sequencer
via paired-end sequencing to obtain 2×50 bp paired
reads. The obtained reads were mapped against the
Homo sapiens genome reference (Ensemble Revision
74, hg19) using the STAR algorithm [23]. FPKM values
were calculated for each sample, differential gene ex-
pression was analyzed using DEseq2 [24]. The genes
with a FPKM value above 0.3 in at least one sample and
a DEseq p-value of 0.05 or better were considered as
differentially expressed if the absolute of the log2 fold
change was one or larger. Differential exon usage was
analyzed using DEXseq [25]. All algorithms used standard
parametrization.
Statistical analysis
Data are expressed as means SD and statistical significance
was determined using an unpaired t-test with GraphPad
Prism 5 (GraphPad Software, La Jolla, U.S.).
Results
Nuclear interaction of galectin-3 with hnRNPA2B1
Renal cell carcinoma RCC FG1 cells [18] were used to
search for nuclear interaction partners of galectin-3. In
a first approach, NE from RCC FG1 cells were immu-
noprecipitated with anti-galectin-3 antibodies, and the
co-precipitated proteins were separated by SDS-PAGE
followed by colloidal coomassie staining of the gels and
analyzed by mass spectrometry (data not shown). Here,
the heterogeneous nuclear ribonucleoprotein A2B1
(hnRNPA2B1) was identified as a galectin-3 interacting
protein (MASCOT score 106; sequence coverage 51.8 %).
To confirm this result and to obtain a more comprehen-
sive view of nuclear galectin-3 interaction partners, we
employed a complementary approach. Recombinant hu-
man galectin-3 was coupled to a sepharose column. The
column was loaded with NE from RCC FG1 cells, washed
intensively and 150 mM lactose was added to release
interaction partners that specifically bind to the lactose-
free form of galectin-3 [26]. Eluted fractions were col-
lected and analyzed by mass spectrometry. In addition
to established interaction partners of galectin-3 both
isoforms of hnRNPA2B1, isoform B1 and A2, were
identified, (Fig. 1a and Additional file 1: Table S1). This ob-
servation confirmed the co-precipitation of hnRNPA2B1
with galectin-3. Moreover, additional hnRNP proteins and
components of the splicing machinery including the spli-
cing auxiliary factor U2AF65 were identified as galectin-3
interactors (Fig. 1a and Additional file 1: Table S1). We also
verified the interaction between galectin-3 and hnRNPA2B1
or U2AF65 by co-immunoprecipitation (Fig. 1b, Additional
file 2: Figure S1). Although we observed some unspecific
binding of hnRNPA2B1 and U2AF65 to protein G beads,
protein G beads loaded with galectin-3 antibodies precipi-
tated significantly higher amounts of hnRNPA2B1 and
U2AF65 (Fig. 1b, Additional file 2: Figure S1, lane 1).
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hnRNPA2B1 is involved in pre-mRNA splicing and
has been detected in the spliceosomal complex [27]. To
test if the hnRNPA2B1/galectin-3 interaction is specific
to RCC cells or if it can also be detected in other cell
types we extended our analysis to HeLa cells. This cell
line is an appropriate model system for our subsequent
investigation of splicing effects, since the function of
hnRNPA2B1 in pre-mRNA splicing in HeLa cells is well
established [28, 29]. We thus performed blue native gel
electrophoresis of HeLa NE to monitor the presence of
hnRNPA2B1 and galectin-3 in nuclear protein com-
plexes. At first, smaller polypeptides including galectin-3
monomers with a molecular weight of about 29 kDa
were depleted from the NE using centricon filters with a
cut-off molecular mass of 50 kDa. The remaining extracts
were then separated sequentially on a native gradient gel
(first dimension) followed by resolving the complexes
according to their molecular weight by SDS-PAGE
(second dimension). As assessed by immunoblot the
distribution patterns of galectin-3 and hnRNPA2B1
along the native gradient are similar with one distinct
maximum in the 10 % range of the first dimension,
suggesting that both proteins co-reside in stable supra-
molecular assemblies or protein complexes (Fig. 1c).
Taken together, our biochemical characterization identi-
fies hnRNPA2B1 as a novel interaction partner of galectin-
3 and suggests that the two proteins form a complex in NE
from RCC FG1 and Hela cells.
We next addressed the question if hnRNPA2B1 and
galectin-3 also colocalize in vivo by immunofluorescence
microscopy. As depicted in Fig. 2a, hnRNPA2B1 showed
strong nuclear staining, whereas galectin-3 was evenly
distributed between cytoplasm and cell nuclei. In the
merged images some of the brighter galectin-3-positive
nuclear spots were also stained by antibodies directed
against hnRNPA2B1, which indicates that both partner
Fig. 1 Interaction of galectin-3 with hnRNPA2B1 in nuclear extracts. hnRNPA2B1 was identified as an interaction partner of galectin-3 by affinity
chromatography (a) and co-immunoprecipitation (b). a Interaction partners of galectin-3 were eluted with lactose from a galectin-3-coupled sepharose
column and analysed by mass spectrometry. Among others, two isoforms of hnRNPA2B1 and the splicing auxiliary factor U2AF65 were identified as
lactose-dependent interaction partners of galectin-3. Numbering on the x axis correlates with Additional file 1: Table S1. b Co-immunoprecipitation of
hnRNPA2B1 with galectin-3. In “Mock” agarose beads control anti-antibodies were used as negative control. c Immuno blot analysis of the second
dimension of a Blue Native PAGE of NE. The percentages of polyacrylamide in the first dimension under native conditions are indicated on the top.
Antibodies used for immunoblot detection are depicted on the left
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proteins accumulate within similar nuclear regions. Fur-
thermore, spatial proximity of galectin-3 and hnRNPA2B1
was tested by employing the in situ PLA, which allows for
improved detection of protein complexes [30]. In this
assay close proximity between the epitopes of two distinct
primary antibodies is required to allow the formation of
amplifiable circularized ligation products. The ampli-
cons were thereafter visualized with fluorescent detec-
tion probes as exemplified in the positive control of
Fig. 2b. Here, primary antibodies against the two veri-
fied binding partners hnRNPA2B1 and SC35 were used
[27]. PLA signals also appeared in the DAPI-stained nuclei
with primary antibodies directed against galectin-3 and
hnRNPA2B1. On the other hand, only a few faint spots
were visible in the complete absence of primary antibodies
as negative control. Quantification of PLA signals per cell
nucleus revealed statistically significant numbers of these
signals in the presence of primary antibodies directed
against hnRNPA2B1 and galectin-3 (Fig. 2c). Thus indi-
cating that hnRNPA2B1 and galectin-3 come into close
proximity within Hela cell nuclei.
Altogether, our biochemical and fluorescence mi-
croscopy data suggest that hnRNPA2B1 interacts with
galectin-3 in the cell nucleus. The idea that both part-
ners are members of a spliceosomal complex is further
corroborated by galectin-3-mediated pulldown of 13
hnRNP proteins and spliceosomal components as identi-
fied by mass spectrometry (Fig. 1a and Additional file 1:
Table S1) or immunoblot/immunofluorescence analysis
(Additional file 2: Figure S1).
Galectin-3 in mRNA-spicing and -export
It has previously been published that hnRNPA2B1 is in-
volved in mRNA-splicing and -export (7) and we sought
to assess the role of galectin-3 in these two processes by
siRNA-mediated galectin-3 depletion. First, HeLa cells
Fig. 2 Localisation of galectin-3 and hnRNPA2B1 in cell nuclei. a HeLa cells were fixed and stained by immunofluorescence with anti-galectin-3/
Alexa Fluor 546 together with anti-hnRNPA2B1/ Alexa Fluor 647. Punctate structures positive for hnRNPA2B1 and endogenous galectin-3 are
indicated by arrows. Nuclear staining (DAPI) is depicted in blue, scale bars: 10 μm. b Interaction between galectin-3 and hnRNPA2B1 was assessed
by in situ PLA. HeLa cells were fixed and incubated with antibodies directed against galectin-3 and hnRNPA2B1. In the negative control HeLa cells
were incubated in the absence of primary antibodies. HeLa cells were incubated with primary antibodies against hnRNPA2B1 and Sc35 as positive
control. Interactions in a proximity up to 40 nm appear as fluorescent dots. Nuclei were stained with DAPI. For a better comparison, nuclei are
depicted in blue, cytoplasmic PLA-signals in magenta and nuclear PLA-signals in dark blue in the merged images. Scale bars; 10 μm. c The amount of
PLA-spots per nucleus was quantified. Bar graphs indicate the average relative number of PLA-signals per nucleus +/− SD, n = 3 (** p = 0.01)
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were transfected with galectin-3-specific siRNA and with
luciferase-siRNA as a control (Fig. 3). Efficient depletion
of galectin-3 was verified by immunoblot from cell ly-
sates (Fig. 3b). To determine the mRNA distribution in
the cell nuclei and in the cytoplasm, in situ hybridization
(FISH) of mRNA with labelled oligo dT-probes was
employed in galectin-3-depleted and control cells. Ratios
of cytoplasmic and nuclear mRNA levels were quantified
from confocal images (Fig. 3c). These data revealed no
significant alterations in the subcellular mRNA distribu-
tion pattern following galectin-3 depletion. Since previ-
ous studies had shown that galectin-3 and galectin-1
exhibit functional redundancy in their splicing activity
and nuclear localisation [31], we decided to knockdown
galectin-1 and −3 simultaneously in Hela cells. This
double knockdown displayed substantial nuclear mRNA-
retention, while a single knockdown of galectin-1 had no
significant implications on the mRNA distribution (Fig. 3c).
Consequently, our data suggest that galectin-3 and
galectin-1 contribute to efficient RNA processing and
export in a redundant fashion.
Even if each of the two galectins can in general com-
pensate the loss of one partner in RNA processing and
export, we decided to search for more subtle galectin-
3-specific effects. To receive a deeper insight into the
specific involvement of galectin-3 in mRNA-splicing,
we sequenced mRNAs from galectin-3 depleted and
control HeLa-cells. Galectin-3-knockdown efficiency
was verified by immunoblot (Additional file 3: Figure S2).
RNA-seq libraries from these cells were sequenced via
paired-end sequencing to obtain 2x50 bp paired reads.
Gross changes in the mRNA expression pattern following
galectin-3 depletion were not observed by RNA-seq data
analysis, which is most likely due to a compensation by
galectin-1 in galectin-3 depleted cells. Nevertheless, a
detailed mRNA sequence analysis revealed statistically
significant alterations in the splicing patterns of several
genes. Especially, genes assigned to transcriptional and
translational regulation, cell metabolism, intracellular
transport or cell proliferation were affected (Fig. 4,
Additional file 4: Table S2). These data are, at the level
of mRNA-processing, in line with previous observa-
tions showing an involvement of galectin-3 in diverse
cellular processes [2, 32]. To strengthen the functional
link of galectin-3 and hnRNPA2B1 in a cancer context
we searched for oncogenes that were similarly affected
by galectin-3 and hnRNPA2B1 knockdown. This search
identified the nuclear oncoprotein SET: As demonstrated
by Goodarzi et al. specific knockdown of hnRNPA2B1
reduces the number of SET-transcripts [33]. Our
RNA-seq data revealed that galectin-3 depletion sig-
nificantly elevates a particularly processed form of
SET-transcripts, which does not code for the protein
(Additional file 4: Table S2). Thus, depletion of either
of the two interaction partners reduces intracellular
levels of SET.
Discussion
Our data demonstrate that galectin-3 interacts with
hnRNPA2B1 in the cell nucleus and that the presence
of galectin-3 modulates mRNA-export and -splicing.
Although we cannot formally rule out that the galectin-
3 binding to hnRNPA2B1 is indirect our ability to de-
tect galectin-3/hnRNPA2B1 complexes in different cell
types using different biochemical approaches argues
that this association is robust. It had already been dem-
onstrated that hnRNPA2B1 is part of the splicing ma-
chinery and is involved in mRNA-processing [34, 35].
The hnRNP proteins A1, A2, B1 and B2, together with C1
and C2 assemble into particles to recruit the newly tran-
scribed pre-mRNA into hnRNPs. They assemble into tetra-
meric (A2)3(B1)- or pentameric (A2)3(B1)(B2)-complexes
in the particle-center with A1, C1 and C2 positioned per-
ipherally [36]. This so-called H-complex of the splicing
pathway has a regulatory function and influences the ability
of particular RNAs to assemble productive splicing com-
plexes. The H-complex is the first step before the initiation
complex starts to recognize the initiation sites (E- and
A-complex) on the pre-mRNA. Then, the B- and C-
complex initiate the two transesterification reactions
leading to exon-joining and intron-release (reviewed in
[37]). Galectin-3 as interaction partner of hnRNPA2B1
in the H-complex would thus be involved in early steps
of spliceosome assembly. This lectin had been already
described as a factor that modulates the activity and
formation of splicing complexes in HeLa cells [17]. It
was also speculated that galectin-3 binds a common
splicing partner through protein-protein interactions [38].
Furthermore, Wang et al. demonstrated that galectin-1
and galectin-3 are functionally redundant splicing factors
as suggested earlier [31], and experiments with the C-
terminal carbohydrate recognition domain of galectin-3
indicate that the amino-terminal domain of the lectin
modulates splicing. Carbohydrates do not seem to be in-
volved in the interaction of galectins with spliceosomal
components as previously described for galectin-1 by
Voss et al. [39]. Additional evidence for the presence of
galectin-3 in spliceosomes comes from colocalisation
experiments with the speckles-marker Sc35 [31] or the
Sm epitopes of the small nuclear ribonucleoprotein
complexes (snRNP) [40]. Moreover, galectin-3 sedimen-
ted in cesium sulfate gradients at densities consistent
with the ones of hnRNPs and snRNPs [16]. These ob-
servations strongly suggest that galectin-3 is a member
of the spliceosomal complex. However, the role and num-
ber of galectin-3-interaction-partners in this process is un-
clear. According to Wang et al. the pre-mRNA as binding
partner could be excluded [38]. Haudek et al. described
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Fig. 3 FISH analysis of Hela cells depleted of galectin-1 and/or galectin-3. a At first HeLa cells were transfected with siRNA to silence galectin-1,
galectin-3 or both proteins. As a control for non-silencing siRNA, the cells were transfected with the firefly luciferase siRNA. Knockdown-efficiency
of galectin-1 and/ or galectin-3 was assessed by immunoblot (b). The cells were fixed and the mRNA was stained with Biotin-oligo(dT)/ Streptavidin-Alexa
Fluor 546. Nuclear staining (DAPI) is indicated in blue, scale bars: 10 μm. c Fluorescent mRNA-staining as depicted in (a) in the cytoplasm and the nucleus
was quantified using the Leica LAS AF software package. Quotients of cytoplasmic divided by nuclear staining +/− SD are depicted. Statistical significant
differences are indicated (n= 9, * P= 0.05 and ** P= 0.005)
Fritsch et al. BMC Cancer  (2016) 16:502 Page 7 of 10
that about 70 % of nuclear galectin-3 is complexed in high
molecular mass particles [41]. They identified the U1-
specific protein, U1 70 K, of the E-complex as galectin-3
interaction partner. We have now found additional binding
partners of galectin-3 by co-immunoprecipitation and mass
spectrometry, which associate at an early stage of spliceo-
some assembly as members of the H-, E- and A-complex,
most prominently hnRNPA2B1 from the H-complex. A pu-
tative role of galectin-3 in H-complex assembly comes from
another study showing that addition of the N-terminal
galectin-3-domain arrested pre-mRNA splicing at a
position corresponding to the H-complex [42]. In that
study, galectin-1 pulled down Gemin4. Fragments of
Gemin4 also exhibited dominant negative effects
when added to a cell-free splicing assay. In addition,
galectin-1 co-immunoprecipitated galectin-3 from NE
[42]. Our isolation of galectin-1 from galectin-3/
sepharose columns confirmed this observation. It thus
seems likely that the two galectins are members of
identical splicing complexes. Another hint for this
idea comes from the functional redundancy of
galectin-1 and −3 as described earlier for pre-mRNA
splicing [31] and which is shown for mRNA-export
by our study. RNA-splicing and nuclear export are
directly linked to each other [43] so that a reduction
in RNA-export efficiency may be due to alterations in
the splicing machinery and/or to the assembly of nu-
clear RNA-binding factors in specifying the cytoplas-
mic fate of an RNA molecule.
The observation, that the number or processing of
RNA-transcripts for the protein SET is affected by both
galectin-3- as well as by hnRNPA2B1-depletion, points to
specific functions of the nuclear galetin-3/hnRNPA2B1-
complex in the regulation of SET expression. Interestingly,
SET expression is deregulated in more than 10 % of kid-
ney cancer samples [44], a cancer type where we have pre-
viously demonstrated increased nuclear translocation of
galectin-3 [18]. SET is a key modulator in cell proliferation
and interacts with hnRNPA2B1 [45]. Moreover, SET and
hnRNPA2B1 are specific inhibitors of the tumor suppres-
sor protein phosphatase 2A (PPA2), a major phosphatase
that controls cell proliferation [45, 46]. Consequently,
Fig. 4 Influence of galectin-3 knockdown on pre-mRNA splicing of isoforms from specific transcripts. HeLa cells were transfected with siRNA to
silence galectin-3 and with the non-silencing control luciferase. As assessed by RNA-sequencing transcripts alternatively spliced following
galectin-3 depletion were sorted by function and shown in the diagram (P ≤ 0.05) (Additional file 4: Table S2)
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our results suggest that in addition to PPA2-inhibition,
hnRNPA2B1 in complex with galectin-3 stimulates cell
proliferation by increasing the number of protein coding
SET-transcripts.
Conclusions
As a conclusion, our data suggest that galectin-3 in associ-
ation with hnRNPA2B1 is involved in the early assembly
of the splicing machinery for mRNA-processing and
nuclear export.
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mAb anti-U2AF65. The precipitated proteins were analysed by immunoblot
with antibodies directed against U2AF65 and galectin-3. Mock is the beads
control without an antibody incubation. (B) HeLa cells were fixed and stained
by immunoflourescence with anti-galectin-3/AlexaFlour 647 and anti-U2AF65/
AlexaFlour 546. Structures positive for U2AF65 and endogenous galectin-3 are
indicated by arrows. Nuclei (Hoechst 33342) are depicted in blue, scale bars:
10 μm. (JPG 1601 kb)
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analysed by immunoblot with anti-galectin-3 and anti-tubulin antibodies as
housekeeping control. (JPG 803 kb)
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galectin‐3 depletion. (PDF 122 kb)
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